The Asian Scientist 100
Lu Ke
Institution
Chinese Academy of Sciences
Country
China
Field
Materials Sciences
Lu is the winner of the 2020 Future Science Prize (Physical Science Prize) for discovering and synthesizing a superior nanotwinned structure and gradient nanostructure.
(Photo: Future Science Prize)
AWARDS
- Future Science Prize 2020
Related articles
MSF Treats First CMV Patients With Oral Drugs
Through a deal brokered with drug manufacturer Roche, CMV patients in Myanmar now need not endure painful injections directly into the eye.
7 Must-Read Stories In July 2014
A round-up of our top stories in July 2014; spanning ancient fossils to cosmic rays and the most high profile retraction in recent years.
India’s Spending Cuts Will Hurt Already Inadequate Health Services
A commentary published in The BMJ has warned that the recently announced health spending cuts will weaken India's public health system.
Hong Kong Doctors Use Microwaves To Treat Liver Cancer
A new type of FDA-approved high efficiency microwave coagulation system has now been tested in Asia by doctors from the University of Hong Kong Li Ka Shing Faculty of Medicine.
Bristol-Myers Squibb Awards Four Grants For Hepatitis Education
To mark World Hepatitis Day 2012, the Bristol-Myers Squibb Foundation has awarded four new grants focused on Hepatitis B and Hepatitis C research in China and India.
PerkinElmer Acquires Chinese Infectious Disease Diagnostics Company
PerkinElmer has acquired Shanghai Haoyuan Biotech to extend its reach into the growing Chinese nucleic acid-based blood screening market.
Gilead Allows India & China To Produce Generic HIV/HBV Drug
An agreement with the Medicines Patent Pool allows generics manufacturers in India and China to produce Gilead's HBV and HIV drug, tenofovir alafenamide.
Watching Evolution In Real-Time
Scientists have developed a method to study the evolution of microbes and cancer cells by detecting mutations as they happen.
Antiviral Therapy For Hep C Improved Diabetes Outcomes
Research from Taiwan has shown that antiviral therapy for hepatitis C virus improved kidney and cardiovascular outcomes for patients with diabetes.